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associated to chronic liver injury that provides a permissive envi-
ronment for cancer development, is characterized by accumula-
tion of extracellular matrix components mainly derived from
activated hepatic stellate cells (HSCs). Axl, a receptor tyrosine
kinase and its ligand Gas6, are involved in cell differentiation,
immune response and carcinogenesis.
Methods: HSCs were obtained from WT and Axl/ mice, treated
with recombinant Gas6 protein (rGas6), Axl siRNAs or the Axl
inhibitor BGB324, and analyzed by western blot and real-time
PCR. Experimental ﬁbrosis was studied in CCl4-treated WT and
Axl/ mice, and in combination with Axl inhibitor. Gas6 and
Axl serum levels were measured in alcoholic liver disease (ALD)
and hepatitis C virus (HCV) patients.
Results: In primary mouse HSCs, Gas6 and Axl levels paralleled
HSC activation. rGas6 phosphorylated Axl and AKT prior to HSC
phenotypic changes, while Axl siRNA silencing reduced HSC acti-
vation. Moreover, BGB324 blocked Axl/AKT phosphorylation and
diminished HSC activation. In addition, Axl/ mice displayed
decreased HSC activation in vitro and liver ﬁbrogenesis after
chronic damage by CCl4 administration. Similarly, BGB324
reduced collagen deposition and CCl4-induced liver ﬁbrosis in
mice. Importantly, Gas6 and Axl serum levels increased in ALD
and HCV patients, inversely correlating with liver functionality.Journal of Hepatology 20
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Activation of hepatic stellate cells (HSCs) is responsible for the
liver ﬁbrosis associated to chronic liver injury of any etiology,
being HSCs the main collagen-producing cells in the damaged
liver [1,2]. Liver ﬁbrosis, critical pre-stage in the development
of liver cirrhosis, may lead to hepatic transplantation or promote
a favorable microenvironment for cancer development [3]. HSCs
transform during chronic liver injury from a quiescent state into
a myoﬁbroblast-like phenotype, which proliferate and migrate
towards areas of necrosis and regeneration [4,5]. Activated
HSCs alter extracellular matrix (ECM) composition due to the
upregulation of proteins such as a-smooth muscle actin
(a-SMA), interstitial collagens such as Collagen 1A1 (COL1A1),
and matrix metalloproteinases (MMPs) such as MMP9, as well
as tissue inhibitor of metalloproteinases (TIMPs), and proteogly-
cans. Activated HSCs also generate hepatic cytokines such as
TGF-b, PDGF, CTGF, FGF, HGF, and VEGF, and recruit inﬂamma-
tory cells, mono- and polymorphonuclear leukocytes that pro-
duce chemokines, including MCP-1, RANTES, CCL21, CCR5.
Although HSC critical role in liver ﬁbrosis was proposed a decade
ago [6], recent data demonstrates that irrespective of the under-
lying etiology of liver disease, the majority of myoﬁbroblasts
come from the liver-resident HSC population [7]. Moreover, after
cessation of the ﬁbrotic triggering insult, around 50% of the acti-
vated HSCs survive in an apparently quiescent state, being
primed to quickly reactivate into myoﬁbroblasts in response to
ﬁbrogenic stimuli [8,9]. Therefore, effective antiﬁbrotic therapies
aimed to inhibit activated HSCs, although positive to prevent
extracellular matrix deposition, may be insufﬁcient to deﬁnitely
revert ﬁbrosis, probably requiring the elimination of activated15 vol. 63 j 670–678
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HSCs for ﬁbrosis resolution in the treatment of chronic liver
disease.
Growth arrest-speciﬁc gene 6 (Gas6) product is a vitamin
K-dependent protein that activates a family of receptor tyrosine
kinases including Axl, MERTK and Tyro3, known as TAM recep-
tors, whose immunologic and oncogenic properties have been
described in detail [10,11]. Among them, Axl receptor signaling
has been related to processes leading to cell differentiation and
carcinogenesis. Gas6 possesses a high structural homology and
sequence identity to the natural anticoagulant protein S (ProS).
However, Gas6 and ProS have clearly different biological roles
[12,13].
In liver pathologies, a hepatoprotective role for Gas6 has been
reported in ischemia/reperfusion-induced damage [14], and in
the wound healing response to liver injury [15,16]. In normal
liver, Gas6 is mainly expressed in Kupffer cells, while Axl is found
in macrophages and in quiescent HSC [17]. Moreover, after acute
CCl4 administration increased Gas6 expression was observed in
activated HSCs and macrophages, while Gas6 in vitro protection
to HSCs was mediated by the Axl/PI3-kinase/AKT pathway [17].
However, the role of Gas6/Axl signaling in chronic liver disease,
the potential use of related proteins as serological markers of dis-
ease progression, and Gas6/Axl targeting in future liver therapies
are aspects that merit further investigation.
To do so, we used both a genetic model of Axl deﬁciency
(Axl/), and a pharmacologic approach, the Axl inhibitor
BGB324 [18]. Our results revealed that Axl receptor is an interest-
ing target to block HSC transformation in vitro and demonstrated
the efﬁcacy of both strategies, genetic and pharmacologic, to
diminish experimental liver ﬁbrosis after chronic administration
of CCl4. Moreover, we analyzed data from patients at different
stages of ALD and HCV infection providing evidence of the
involvement of the Gas6/Axl axis in human liver ﬁbrosis, and
showing the correlation between Gas6/Axl serum levels and liver
dysfunction.
In conclusion, our results underscore a critical role of the
Gas6/Axl in ﬁbrogenesis and in the progression of chronic liver
diseases, suggesting that therapies aimed to inhibit Axl signaling
deserve to be undertaken for the treatment of liver ﬁbrosis, par-
ticularly now that small molecule inhibitors of Axl have been
tested in clinical trials for cancer treatment [19].Materials and methods
Animal procedures
All procedures were performed according to protocols approved by the Animal
Experimentation Ethics Committee from the University of Barcelona. In vivo liver
ﬁbrogenesis was analyzed after chronic carbon tetrachloride (CCl4) administra-
tion. To this aim, WT or Axl/ mice were treated with CCl4 at a dose of 5 ll
(10% CCl4 in corn oil)/g of body weight, by intraperitoneal injection twice a week
for ﬁve-six weeks. Control animals received corn oil alone. Treatment with Axl
inhibitor (BGB324) or vehicle (saline solution) was performed daily for the last
ten days of the study via oral gavage at a dose of 80 lg/g body weight. In previous
experiments with rodents at similar doses, BGB324 reached serum concentration
in the low micromolar range [18], being safe for animal treatment. Control ani-
mals received vehicle alone.
HSCs isolation and culture
Wild type and Axl knockout mice livers (male, 8–10 week-old littermates)
(C57BL/6 strain) were perfused with collagenase and HSCs cultured as previously
described [20,21]. Culture purity, assessed routinely by retinoid autoﬂuorescenceJournal of Hepatology 201at 350 nm, was >95%. Lack of staining for F4/80 conﬁrmed the absence of Kupffer
cells. HSCs and LX2 human activated stellate cells [20,22] were cultured in DMEM
supplemented with 10% FBS and antibiotics at 37 C in a humidiﬁed atmosphere
of 95% air and 5% CO2. Experiments to compare protein or mRNA content were
always performed with cells extracted at the same time of culture, previously
treated with recombinant Gas6 (R&D), Axl inhibitor (BGB324, BerGenBio), or
siRNA silencing (Santa Cruz) after Lipofectamine 2000 exposure for the indicated
periods of time.
SDS-PAGE and immunoblot analysis; RNA isolation and real-time RT-PCR; In Vitro
Small Interfering RNA Transfection; Nuclear extract isolation; Immunohistochemical
staining; and liver collagen determination
These methods were performed as previously indicated [20,21,23] with modiﬁca-
tions as speciﬁed in Supplemental methods.
Determination of Gas6, and soluble Axl (sAxl) levels
Measurements of Gas6 and sAxl human levels were carried out using commercial
antibodies (R&D Systems) to develop speciﬁc ELISAs that use the sandwich tech-
nique as described [24]. Serum Gas6 mouse levels were determined using a com-
mercial kit (DuoSet mGas6 ELISA, R&D). Serum sAxl mouse levels were
determined by western blot.
Human samples
a) The ALD study group comprised serum samples from 40 individuals: ten
healthy normal adult controls (C) and 30 alcoholic patients with different degrees
of liver disease as diagnosed after hepatic biopsy and Fibroscan measurement:
ten patients with initial ﬁbrosis (Fibroscan score 67 KPa, mean = 5.2 ± 0.4) (F),
ten patients with compensated cirrhosis (CH) and, 10 patients with decompen-
sated cirrhosis (DCH), ﬁve of them due to ascitis, three due to spontaneous bac-
terial peritonitis (SBP) and two due to gastrointestinal bleeding by esophageal
varices and portal hypertension. Relevant biochemical data are shown in
Table 1. b) The HCV study group comprised serum samples from 51 individuals
at different stages of liver ﬁbrosis (8 F0, 15 F1, 17 F2, and 11 F3/F4), as stated
by liver biopsies, before initiation of treatments. None of the HCV patients exhib-
ited signs of decompensation. Relevant biochemical data are shown in Table 2. All
subjects gave written informed consent in accordance with the Declaration of
Helsinki, and the protocol, approved by ethical committees from the Hospital
Clinic, followed ethical guidelines on handling human samples.
Statistical analyses
Results are expressed as mean ± standard deviation, unless indicated, with the
number of individual experiments detailed in Figure legends. Statistical compar-
isons were performed using unpaired two-tailed Student’s t test or One-way
ANOVA followed by Newman-Keuls Multiple Comparison Test (GraphPad
Prism). A p value less than 0.05 was considered signiﬁcant.Results
TAM receptors and ligands levels during HSC activation
Gas6 and ProS are the ligands of the tyrosine kinase family of
receptors named TAM (Tyro3, Axl, and MERTK), which have been
involved in numerous processes related to cell transformation
and cancer. Since TAM receptor participation in HSC activation
has not been explored, we analyzed the presence of transcrip-
tional changes during HSC transdifferentiation in mouse-
derived primary cultures of HSCs. A signiﬁcant increase in the
mRNA levels of Gas6, but not of ProS, was detected (Fig. 1A). In
parallel, strong upregulation of Axl was observed, with no signif-
icant changes in MERTK levels (Fig. 1B). Tyro3 mRNA levels were
not detectable in these samples. Of note, increased secretion of
Gas6 protein expression was conﬁrmed in HSCs after different
days in culture, as determined by ELISA in 24 h cell conditioned5 vol. 63 j 670–678 671
Table 1. Biochemical data from the ALD patients and control serums analyzed for Gas6 and sAxl levels.
Cirrhotic decompensated
m (9) — f (1)
Cirrhotic compensated
m (7) — f (3)
Initial fibrosis
m (9) — f (1)
Control values
m (6) — f (4)
Age 50.6 ± 6.3 59.2 ± 5.8 48.3 ± 10.1 51.7 ± 10.4
Billirubin (mg/dl) 2.6 ± 3.4 * 1.5 ± 1.5 0.76 ± 0.44 0.2 — 1.0
Albumin (g/L) 31.6 ± 7.2 * # 41.8 ± 4.1 44.5 ± 1.6 35 — 50
Quick (%) 60.2 ± 21.7 * # 76.6 ± 17.2 * 97.9 ± 4.8 70 — 100
MELD 14.7 ± 5.1 * # 10.3 ± 3.7 7.1 ± 1.1 6.43
Creatinin (mg/ml) 0.97 ± 0.26 0.98 ± 0.17 0.81 ± 0.16 0.6 — 1.2
AST (U/L) 47.8 ± 45.0 32.0 ± 9.7 21.5 ± 10.0 10 — 40
ALT (U/L) 22.1 ± 13.1 24.8 ± 7.2 23.0 ± 10.8 10 — 35
GGT (U/L) 106.4 ± 119.0 54.5 ± 38.7 35.4 ± 51.8 5 — 40
For the control group, serums from ten individuals (six males and four females with average age of 51.7 ± 10.4) were used to measure Gas6 and Axl levels. Reference ranges
for the each biochemical parameter are provided (right column), as established for normal individuals according to Hospital Clinic Core Lab (Barcelona, Spain). m = male;
f = female. *p 60.05 vs. initial ﬁbrosis group (F), #p 60.05 vs. cirrhotic compensated group (CH). One-way ANOVA, Newman-Keuls Multiple Comparison Test.
Table 2. Biochemical data from the serum of HCV patients analyzed for Gas6 and sAxl levels.
F0
m (2) — f (6)
F1
m (10) — f (5)
F2
m (11) — f (6)
F3/F4
m (9) — f (2)
Age 41.6 ± 3.8 46.1 ± 2.4 50.2 ± 2.5 53.5 ± 2.8
Billirubin (mg/dl) 0.5 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 1.2 ± 0.2
Albumin (g/L) 44.7 ± 1.2 44.8 ± 0.5 43.8 ± 0.8 41.1 ± 1.3 #
Quick (%) 96.1 ± 2.0 94.4 ± 1.4 90.4 ± 0.7 82.5 ± 3.3 * # &
MELD 7.1 ± 0.3 7.8 ± 0.3 8.4 ± 0.3 9.7 ± 0.6 * #
Creatinin (mg/ml) 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.1
AST (U/L) 48.3 ± 5.7 48.8 ± 4.7 83.1 ± 14.0 95.5 ± 10.9
ALT (U/L) 74.5 ± 15.9 77.9 ± 10.9 125.5 ± 18.1 108.7 ± 11.9
GGT (U/L) 60.3 ± 13.8 44.2 ± 9.1 70.5 ± 14.1 128.3 ± 44.2
m =male; f = female. *p 60.05 vs. F0 group. #p 60.05 vs. F1 group. &p 60.05 vs. F2 group. One-way ANOVA, Newman-Keuls Multiple Comparison Test.
Research Articlemedium (Fig. 1C). Thus, the activation of WT HSCs is paralleled by
an increase in expression of Axl, and the expression and secretion
into the medium of Gas6.
Axl is required for full HSC activation and proliferation in vitro
To verify the repercussion of this correlation in HSC transforma-
tion, we analyzed the effect of reducing the expression of Axl in
activated HSCs, by means of RNA silencing, and the consequences
of Gas6 supplementation. Since primary HSCs are not easy to
manipulate genetically, we used the LX2 human activated HSC
cell line. LX2 cells with depleted Axl levels by siRNA transfection
displayed a signiﬁcant reduction in a-SMA levels (Fig. 2A).
Moreover, we tested if recombinant Gas6 (rGas6) may further
increase LX2 cells activation, and observed enhanced levels of
a-SMA in LX2 exposed to rGas6 for up to three days (Fig. 2B),
compared to cells treated with vehicle (PBS). In addition, rGas6
administration induced a fast Axl and AKT phosphorylation in
LX2 cells (Fig. 2C). Of note, Gas6-dependent AKT activation was
responsible for the nuclear translocation of the anti-apoptotic
NF-jB subunit p65, since it was detected in nuclear extracts of
LX2 cells immediately after rGas6 administration, while PI3K
inhibitor LY294002 blocked p65 nuclear upregulation. These
results, in line with previous observations in activated HSCs
[17], supported the participation of Gas6 activation on the672 Journal of Hepatology 201proliferation and survival of HSCs via the AKT/NF-jB signaling
pathways. However, since we also observed that rGas6 phospho-
rylated MERTK (Fig. 2C), at this point we cannot discard a poten-
tial role of MERTK in HSC signaling.
To better examine Axl contribution, HSCs from Axl/ mice
were obtained, cultured and analyzed in comparison to WT
HSCs. A signiﬁcant reduction in the mRNA levels of the markers
for HSC activation a-SMA and Col1a1 was observed in Axl deﬁ-
cient mice, as well as in TIMP-1 mRNA, while no differences for
TGF-b levels were detected (Fig. 2D). Indeed, Axl/ HSCs showed
decreased protein levels of a-SMA in vitro, showing a reduced
activation state after 10 days and delayed proliferation, as mani-
fested by MMP9 and PCNA levels, respectively (Fig. 2E). Although
not all the variety of proteins induced during HSC activation are
affected by Axl, as the absence of changes in TGF-b seem to indi-
cate, taken as a whole, these results suggest that Axl signaling is
required for full activation of HSCs in vitro.
Axl deﬁciency diminished liver ﬁbrosis induced by carbon
tetrachloride
To investigate if Gas6/Axl role in HSC activation in vitro may
reﬂect a key participation of this system in the development of
liver ﬁbrosis, we used the chronic administration of CCl4 as a
model to generate liver damage and ﬁbrogenesis in mice. First,5 vol. 63 j 670–678
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Fig. 1. Gas6 and Axl levels are increased in WT HSCs during in vitro activation.
(A and B) mRNA expression level of Gas6, ProS, Axl, andMERTK in HSCs at different
times of in vitro activation, using b-actin as control. (n P3). (C) Gas6 protein
levels released to fresh culture medium during 24 h from HSCs at different time
points of in vitro activation, detected by ELISA and corrected by cellular protein
content. (n = 3). *p 60.05, Student’s t test.
JOURNAL OF HEPATOLOGYwe wanted to analyze if Gas6 and Axl levels are modiﬁed in ani-
mals suffering liver ﬁbrosis. After ﬁve weeks of CCl4 treatment
mice exhibited increased Gas6 and sAxl serum levels compared
to oil-treated animals (Fig. 3A), indicating that this pathway is
upregulated during CCl4-induced liver ﬁbrosis. Second, we ana-
lyzed in Axl/ mice the effect of CCl4 administration. After ﬁve
weeks, liver hydroxyproline levels, indicative of collagen deposi-
tion, were signiﬁcantly lower in Axl deﬁcient animals treated
with CCl4 (Fig. 3B), suggesting reduced liver ﬁbrosis as conﬁrmed
in liver sections after Sirius Red staining and quantiﬁcation
(Fig. 3C and D). In accordance, liver homogenates exhibited an
increase in a-SMA and MMP9 after CCl4 administration thatJournal of Hepatology 201was reduced in Axl/ mice (Fig. 3E) indicative of HSC activation
and changes in ECM composition. Analogously, a-SMA stained
liver slides from CCl4-treated Axl/mice exhibited similar reduc-
tion (Supplementary Fig. 1A). Finally, we checked the degree of
liver injury to verify that the lower liver ﬁbrosis observed in
Axl/ mice is not a consequence of reduced hepatocellular dam-
age induced by CCl4. Both WT and Axl deﬁcient mice displayed
similar ALT levels after CCl4 exposure, which allows discarding
reduced liver ﬁbrosis as a consequence of lesser hepatic damage.
It has been proposed that Gas6 deﬁciency could lead to a
decline in liver ﬁbrosis after CCl4 exposure due to reduced macro-
phage recruitment [25]. Therefore, we decided to analyze poten-
tial differences in liver inﬂammation and immune cell
recruitment to the liver. When we quantiﬁed the mRNA levels
of inﬂammatory cytokines (TNF), chemokines (MCP-1) or neu-
trophil inﬁltration (MPO) in WT and Axl/ CCl4-treated mice
they were similarly increased, as compared to their untreated
controls (Supplementary Fig. 1B and D). In addition, no changes
in MPO staining were observed between WT and Axl/
CCl4-treated animals (Supplementary Fig. 1C). However, a minor
level of macrophages (F4/80) and newly-recruited monocytes/-
macrophages (CCR2) were detected in the livers of Axl deﬁcient
mice after CCl4 exposure (Supplementary Fig. 1D). These results
support a role for the Gas6/Axl pathway in macrophage response
to CCl4 exposure, as previously indicated [25], and are in line with
other models of tissue damage such as advanced atherosclerotic
plaques in GAS6 deﬁcient animals [26].
BGB324, small molecule inhibitor of Axl, blocks HSC activation
in vitro and reduces CCl4-induced liver ﬁbrosis in WT mice
Axl is an attractive target for the treatment of different human
pathologies, particularly in cancer. Interestingly, a small molecule
inhibitor of Axl (BGB324, BerGenBio) has entered clinical trials for
cancer treatment. We tested the effect of BGB324 administration
for 24 h on seven-day old WT HSC cells (Fig. 4A). Axl inhibitor
administration was able to reduce the activation of primary
HSCs, even inducing HSC elimination at higher doses in the
micromolar range (Fig. 4A, upper image). This effect was speciﬁc
for Axl inhibition since BGB324 administration did not affect
MERTK phosphorylation (Fig. 4A, lower image), while effectively
blocked AKT activation after short-term incubation with rGas6
(30 min., 200 ng/ml) (Fig. 4B).
To analyze whether inhibition of Axl, using BGB324, may play
a role in the progression of liver ﬁbrogenesis, mice were injected
CCl4 twice weekly to stimulate HSC activation and promote liver
ﬁbrosis. After four weeks, animals started receiving BGB324
co-treatment via oral gavage on a daily basis for ten additional
days. Determination of the hepatic hydroxyproline content
showed a signiﬁcant decrease in the accumulation of collagen
ﬁbers in animals treated with CCl4 that received Axl inhibitor
compared to control animals (Fig. 4C). This result was conﬁrmed
after Sirius Red staining, showing less deposition of collagen
ﬁbers in animals treated with BGB324 and CCl4, compared to
CCl4-vehicle treated mice (Fig. 4D), as denoted by the
quantiﬁcation of collagen content in different sections (Fig. 4E).
Moreover, mice that received BGB324 exhibited reduced levels
of MMP9 and a-SMA after CCl4 exposure (Supplementary
Fig. 2A), and diminished a-SMA staining in liver slides compared
to CCl4-treated mice without inhibitor administration
(Supplementary Fig. 2B), conﬁrming changes in ECM composition5 vol. 63 j 670–678 673
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Research Articleand HSC activation. Of note, serum levels of ALT after CCl4
administration were similar in vehicle and Axl inhibitor-treated
mice indicating that the antiﬁbrotic effect of BGB324 is not a
consequence of reduced hepatocellular damage after chemical
exposure (Fig. 4F).
Interestingly, when we analyzed changes in liver inﬂamma-
tion and immune cell recruitment to the liver induced by
BGB324, we obtained results in accordance with the data pro-
vided by the Axl/ mice. While a comparable degree of TNF,
MCP-1 or neutrophil inﬁltration was observed in all
CCl4-treated mice (Supplementary Fig. 2C and D), animals that
received BGB324 exhibited decreased macrophage recruitment
(Supplementary Fig. 2D), in line with previous results observed
analyzing Gas6 KO mice [25].
Serum levels of Gas6 and sAxl correlate with liver dysfunction in
human ALD, and increased during HCV-induced ﬁbrosis progression
Serum levels of Gas6 and/or sAxl have been related to cancer
prognosis and to other pathologies, such as heart failure or sepsis
[27,28]. Since our results point to Gas6/Axl axis as a relevant sig-
naling pathway in liver ﬁbrogenesis, we decided to evaluate this
pathway in patients with different degrees of ALD in which pro-
gression from asymptomatic ﬁbrosis to decompensated cirrhosis
is a well-studied process [29]. Therefore, we determined Gas6
and sAxl concentration in serum samples from alcoholic patients
in initial (F0/F1) stages of liver ﬁbrosis (F), patients with compen-
sated (CH), and patients with decompensated hepatic cirrhosis674 Journal of Hepatology 201(DCH), and compared them to control individuals (C). Both
Gas6 and sAxl were found increased in serum levels of cirrhotic
patients, showing close correlation with the severity of the dis-
ease, although behaving differently. Speciﬁcally, sAxl concentra-
tion was already augmented in individuals with compensated
cirrhosis compared to initial ﬁbrosis (Fig. 5B), while Gas6 levels
were increased markedly in the DCH group (Fig. 5A).
To verify this observation, we examined the relationship
between the serum levels of Gas6 and sAxl compared to the
Model for End-Stage Liver Disease (MELD) score system, which
assigns a value calculated from different biochemical parameters
altered in chronic liver disease. The analysis revealed a remark-
able correlation between the MELD score and both proteins
(Fig. 5C and D), being better for Gas6 serum levels (r2 = 0.78).
Interestingly, we identiﬁed an algorithm containing sAxl and
Gas6 that can achieve even stronger correlation (r2 = 0.86) with
the MELD score (Fig. 5D), suggesting that the measurement of
both proteins provides a better evaluation of liver functionality.
However, since our ALD group contains only individuals with
early F0/F1 ﬁbrosis and with cirrhosis, compensated or decom-
pensated, our measurements did not allow to verify an increase
in the Gas6/Axl system during the progression of ﬁbrosis, or to
validate Gas6/Axl detection in other human hepatic pathologies.
To do so, we analyzed Gas6 and sAxl levels in the serum of
HCV patients at different stages of liver ﬁbrosis before starting
treatments (Fig. 5E and F). Our data revealed that Gas6 levels
were signiﬁcantly different between individual with established
ﬁbrosis (F2) and patients with initial ﬁbrosis (F0 and F1 groups).5 vol. 63 j 670–678
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JOURNAL OF HEPATOLOGYIn addition, sAxl levels displayed signiﬁcant changes between
patients with F2 ﬁbrosis and individuals with advanced ﬁbrosis
or cirrhosis (F3/F4 group). These ﬁndings underscore the rele-
vance of the Gas6/Axl pathway during the development of ALD-
and HCV-induced liver damage, supporting Gas6 and sAxl serum
levels as indicative parameters of hepatic dysfunction and ﬁbro-
sis development in liver disease.Discussion
HSC transdifferentiation represents a crucial cell reprogramming
event that shifts HSCs from a normal vitamin A-storing to an
ECM-remodeling phenotype that favors tumorigenic develop-
ment [4]. Despite recent progress in understanding the biology
of HSCs, the mechanisms are not yet fully known. In fact, besides
the treatment/withdrawal of the underlying cause, ﬁbrosis
regression in chronic liver diseases is not accomplished by any
antiﬁbrotic drug despite the experimental description of an arrayJournal of Hepatology 201of pharmacological targets [1,5]. In this context, the characteriza-
tion of the role of Gas6/Axl pathway in liver ﬁbrosis, by partici-
pating in the activation of HSC may provide a new therapeutic
target, not only for liver ﬁbrosis, but also for different chronic
liver diseases. Moreover, the existence of speciﬁc Axl inhibitors
[30], already in clinical trials, may facilitate the biomedical trans-
lation of our results (Fig. 6).
Here, we used BGB324 (BerGenBio), an inhibitor of Axl ready
to reach Phase Ib clinical trials for cancer treatment after showing
good tolerability by healthy volunteers in doses up to 1.5 g/daily
with a long plasma half-life [31]. BGB324 is highly speciﬁc for Axl
inhibition, having exhibited >100-fold selectivity for Axl vs. Abl
and 50- and >100-fold selectivity over TAM family kinases
MERTK and Tyro3, respectively, in cells-based assays [18]. In fact,
we observed that at doses effective to block AKT phosphorylation
and HSC activation, BGB324 did not alter MERTK phosphorylation
by rGas6. Although, based in our data, we cannot discard
other off-target effects of BGB324 administration, the highly5 vol. 63 j 670–678 675
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Research Articlesimilar results obtained between the Axl/ mice and the
BGB324-treated mice suggest that the anti-ﬁbrotic action of
BGB324 is mainly due to Axl inhibition.
High levels of Axl expression have been observed in many
types of cancer correlating with poor survival; among them
glioblastoma multiforme [32], acute myeloid leukemia [33],
breast cancer [34], osteosarcoma [35] and renal cell carcinoma
[36]. Moreover, Axl activation is a mechanism of drug resistance
to therapies targeting EGFR mechanism in lung cancer [37].
However, Axl and MERTK are also expressed by macrophages
and dendritic cells, where they limit excessive immune response
[10,38]. This aspect has raised concerns and could limit the use of
TAM receptors as targets in cancer, in special since blockage of
Axl/ MERTK promote the development of tumor growth in an
inﬂammatory environment such as colon cancer [39], a tumor
that beneﬁts of a pro-inﬂammatory milieu similarly as liver can-
cer does. Importantly, this deleterious effect seems to require the
simultaneous absence of both kinases (Axl and MERTK) activities
[40], and BGB324 is already effective at doses that provide serum676 Journal of Hepatology 201concentration in the low micromolar range, with minimal afﬁnity
for MERTK [18]. This observation is supported by our results in
mice, not having detected inﬂammation in treated animals, dis-
playing similar levels of neutrophil inﬁltration after CCl4 admin-
istration. In fact, BGB324 has just received orphan-drug
designation from FDA in the treatment of acute myeloid leuke-
mia, supporting its good tolerability and lack of side-effects in
clinical trials. In this sense, BGB324 accomplished a feature
required to Axl inhibitors for systemic administration in cancer,
particularly for hepatocellular carcinoma, to act without favoring
a pro-carcinogenic background. Of note, other approaches to
block Axl signaling are already under study, for instance an Axl
’decoy receptor’ has been recently engineered, showing capacity
to inhibit metastasis and cancer progression in vivo [40].
Therefore, BGB324 and other molecules that antagonize the
Gas6/Axl pathway deserve to be further analyzed in the context
of advanced liver ﬁbrosis, and most probably of liver cancer
development.
Several reports have positioned Gas6 as a protective molecule
against ischemia/reperfusion [14] and promoter of liver regener-
ation after acute liver damage [15,16], while its deﬁciency was
associated to decreased liver ﬁbrosis [25]. We considered using
Gas6 KO mice to analyze Gas6/Axl system in HSC activation but
previous results showing compensatory alterations such as Axl
overexpression in the liver [25], refrained us to do it. In fact,
we veriﬁed in murine Gas6/ HSCs high expression of Axl,
increased AKT phosphorylation, and elevated a-SMA levels,
among other markers of HSC activation (Supplementary Fig. 3).
Since Gas6/Axl axis is not blocked in Gas6/ HSCs, we preferred
to use the Axl/mouse model instead. In this sense, our data tar-
geting directly Axl underscore the importance of Gas6/Axl path-
way in liver disease, being supported by similar results
obtained after administration of the small molecule inhibitor
BGB324.
Although it has been reported an increase in Gas6/Axl pro-
teins in patients with hepatocellular carcinoma from different
etiologies [41], and sAxl levels are increased in end-stage heart
failure patients undergoing heart transplantation [27], which5 vol. 63 j 670–678
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frequently suffer cardiac ﬁbrosis, Gas6/Axl as serological markers
of liver function have not been previously proposed. We have
conﬁrmed in serum samples from ALD and HCV patients an
enhancement in Gas6 and sAxl serum levels. Although we can
not discard that the prominent increase in Gas6/Axl observed in
these ALD cirrhotic patients may be partially due to a deﬁcient
liver protein clearance, the observation that a similar increase
is also detected in ﬁbrotic HCV patients, even in patients without
cirrhosis, suggests otherwise. Moreover, an algorithm combina-
tion of Gas6 and sAxl levels display an excellent correlation with
the degree of liver dysfunction in ALD patients determined by the
MELD index (r2 = 0.86 for sAG index) suggesting that the mea-
surement of both proteins provides additional information to
analyze liver functionality. In this sense, we consider that preclin-
ical research may also beneﬁt from Gas6/Axl levels to measure
ﬁbrosis progression, since numerous targets for antiﬁbrotic
agents have problems to be analyzed or to enter early-phase clin-
ical studies due to the lack of sensitive markers to follow the
effects [42]. These results point to Gas6/sAxl determination as a
signiﬁcant diagnostic tool for chronic liver disease, and help us
to position Gas6/Axl signaling pathway as a relevant in human
liver pathology.
In conclusion, Gas6/Axl is a proﬁbrogenic route that is acti-
vated in patients with chronic liver disease. Therefore, small
molecule inhibitors against Axl, that effectively eliminate HSC
activation and reduce experimental ﬁbrosis progression, may be
an interesting therapeutic tool for future clinical trials.Financial support
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